Shares of Repros Therapeutics Inc. (RPRX) were up 48% in extended trading on Tuesday, following positive results from the company’s phase 2b study of vaginal Proellex in women with severe menstrual bleeding due to uterine fibroids.
Forex – financial instrument.Forex news
Shares of Repros Therapeutics Inc. (RPRX) were up 48% in extended trading on Tuesday, following positive results from the company’s phase 2b study of vaginal Proellex in women with severe menstrual bleeding due to uterine fibroids.